Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

Product portfolio
Potentially strong market reviews
Competitive analytics
Prospect partners
Mergers and acquisitions project data
Latest trends across a particular industry area
Research and development strategies
The analysis of new customers
A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853

Sort by:

Small Intestine Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Small Intestine Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Small Intestine Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type an...

May 2022 46 pages

Smoking Cessation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Smoking Cessation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Smoking Cessation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Play...

May 2022 53 pages

Social Anxiety Disorder (SAD-Social Phobia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Social Anxiety Disorder (SAD-Social Phobia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Social Anxiety Disorder (SAD/Social Phobia) Drugs in Development by...

May 2022 39 pages

Sodium Channel Protein Type 8 Subunit Alpha (Voltage Gated Sodium Channel Subunit Alpha Nav1.6 or SCN8A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 8 Subunit Alpha (Voltage Gated Sodium Channel Subunit Alpha Nav1.6 or SCN8A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 52 pages

Sodium Dependent Dopamine Transporter (DA Transporter or DAT or Solute Carrier Family 6 Member 3 or SLC6A3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Dependent Dopamine Transporter (DA Transporter or DAT or Solute Carrier Family 6 Member 3 or SLC6A3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and K...

May 2022 102 pages

Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type an...

May 2022 94 pages

Sodium-Glucose Cotransporter 1 (High Affinity Sodium-Glucose Cotransporter or Solute Carrier Family 5 Member 1 or SGLT1 or SLC5A1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium-Glucose Cotransporter 1 (High Affinity Sodium-Glucose Cotransporter or Solute Carrier Family 5 Member 1 or SGLT1 or SLC5A1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 45 pages

Sodium-Glucose Cotransporter 2 (Low Affinity Sodium-Glucose Cotransporter or Solute Carrier Family 5 Member 2 or SGLT2 or SLC5A2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium-Glucose Cotransporter 2 (Low Affinity Sodium-Glucose Cotransporter or Solute Carrier Family 5 Member 2 or SGLT2 or SLC5A2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, Ro...

May 2022 76 pages

Soft Tissue Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Soft Tissue Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Soft Tissue Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key...

May 2022 310 pages

Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 (Glucose Transporter Type 1 Erythrocyte-Brain or GLUT1 or HepG2 Glucose Transporter or SLC2A1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 (Glucose Transporter Type 1 Erythrocyte-Brain or GLUT1 or HepG2 Glucose Transporter or SLC2A1) Drugs in Development by Therapy Areas an...

May 2022 40 pages

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Somatostatin Receptor Type 2 (SRIF1 or SSTR...

May 2022 43 pages

Somatostatin Receptor Type 5 (SSTR5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Somatostatin Receptor Type 5 (SSTR5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Somatostatin Receptor Type 5 (SSTR5) Drugs in Develo...

May 2022 45 pages

Spasmodic Torticollis (Cervical Dystonia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Spasmodic Torticollis (Cervical Dystonia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Spasmodic Torticollis (Cervical Dystonia) Drugs in Development by Stag...

May 2022 36 pages

Sphingosine 1-Phosphate Receptor (S1PR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sphingosine 1-Phosphate Receptor (S1PR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Sphingosine 1-Phosphate Receptor (S1PR) Drugs in...

May 2022 69 pages

Spinal Cord Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Spinal Cord Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Spinal Cord Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and...

May 2022 146 pages

Spinal Stenosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Spinal Stenosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Spinal Stenosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players...

May 2022 36 pages

Splenic Marginal Zone B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Splenic Marginal Zone B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Splenic Marginal Zone B-Cell Lymphoma Drugs in Development by Stages, Targ...

May 2022 54 pages

Squalene Monooxygenase (Squalene Epoxidase or SQLE or EC 1.14.14.17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Squalene Monooxygenase (Squalene Epoxidase or SQLE or EC 1.14.14.17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Squalene Monooxygena...

May 2022 37 pages

Squamous Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Squamous Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Squamous Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 165 pages

Squamous Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Squamous Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Squamous Non-Small Cell Lung Cancer Drugs in Development by Stages, Target,...

May 2022 148 pages

Squamous Non-Small Cell Lung Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Squamous Non-Small Cell Lung Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Squamous Non-Small Cell Lung Carcinoma Drugs in Development by Stages, Ta...

May 2022 43 pages

Staphylococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Staphylococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Staphylococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 301 pages

Staphylococcus aureus Alpha Hemolysin (Alpha Toxin or hly) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Staphylococcus aureus Alpha Hemolysin (Alpha Toxin or hly) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Staphylococcus aureus Alpha He...

May 2022 38 pages

Staphylococcus Aureus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Staphylococcus Aureus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Staphylococcus Aureus Infections Drugs in Development by Stages, Target, MoA, R...

May 2022 292 pages

Status Epilepticus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Status Epilepticus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Status Epilepticus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Pl...

May 2022 40 pages

Streptococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Streptococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Streptococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...

May 2022 60 pages

Streptococcal Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Streptococcal Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Streptococcal Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 115 pages

Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecu...

May 2022 41 pages

Subacute Necrotizing Encephalomyelopathy (Leigh Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Subacute Necrotizing Encephalomyelopathy (Leigh Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Subacute Necrotizing Encephalomyelopathy (Leigh Disease...

May 2022 40 pages

Subarachnoid Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Subarachnoid Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Subarachnoid Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 43 pages

Substance (Drug) Abuse Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Substance (Drug) Abuse Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Substance (Drug) Abuse Drugs in Development by Stages, Target, MoA, RoA, Molecule Type an...

May 2022 88 pages

Substance P Receptor (Tachykinin Receptor 1 or NK 1 Receptor or NK1R or TACR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Substance P Receptor (Tachykinin Receptor 1 or NK 1 Receptor or NK1R or TACR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Substance...

May 2022 52 pages

Surface Protein gp120 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Surface Protein gp120 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Surface Protein gp120 Drugs in Development by Therapy Areas and Ind...

May 2022 62 pages

Surgical Wound Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Surgical Wound Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Surgical Wound Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 37 pages

Synaptic Functional Regulator FMR1 (Fragile X Mental Retardation Protein 1 or FMRP or FMR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Synaptic Functional Regulator FMR1 (Fragile X Mental Retardation Protein 1 or FMRP or FMR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMA...

May 2022 35 pages

Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Pl...

May 2022 51 pages

Systemic Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Systemic Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Systemic Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Ke...

May 2022 55 pages

Systemic Idiopathic Juvenile Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Systemic Idiopathic Juvenile Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Systemic Idiopathic Juvenile Arthritis Drugs in Development by Stages, Ta...

May 2022 37 pages

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Systemic-Onset Juvenile Idiopathic Arthritis (Still...

May 2022 54 pages

Systolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Systolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Systolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type an...

May 2022 49 pages

T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY T-Cell Acute Lymphocytic Leukemia (T-Ce...

May 2022 79 pages

T-Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

T-Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY T-Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players...

May 2022 81 pages

T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Player...

May 2022 263 pages

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY T Cell Specific Surface Glycopro...

May 2022 58 pages

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3-Leu 4 Epsilon Chain or CD3E) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3-Leu 4 Epsilon Chain or CD3E) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Pla...

May 2022 43 pages

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4-Leu 3 or CD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4-Leu 3 or CD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY T Cell Surface G...

May 2022 49 pages

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Pl...

May 2022 43 pages

TAR DNA Binding Protein 43 (TDP43 or TARDBP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

TAR DNA Binding Protein 43 (TDP43 or TARDBP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY TAR DNA Binding Protein 43 (TDP43 or TARDBP)...

May 2022 51 pages

Tauopathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Tauopathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Tauopathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides...

May 2022 69 pages

Tay-Sachs Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Tay-Sachs Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Tay-Sachs Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Play...

May 2022 47 pages